The SKYTROFA^® Difference

SKYTROFA is the first FDA-approved once-weekly treatment for pediatric GHD that delivers somatropin, which is used in daily growth hormone therapies.

What is SKYTROFA?

Once-weekly SKYTROFA:

Is used to treat pediatric growth hormone deficiency (GHD) in children aged 1 year and older who weigh at least 11.5 kg (25.35 lb)
Provides somatropin, which is used in daily growth hormone injections
Was designed to deliver your child’s medicine with extended-release technology
Has an established safety profile

Nurse at table with family discussing SKYTROFA

Not an actual patient.

Features of SKYTROFA

More injection-free days compared with daily therapies

Higher growth rate after 1 year in a clinical trial compared with a daily somatropin therapy^†

Convenient storage with no required refrigeration for up to 6 months* and preservative free

Clinical data for pediatric patients switching from a daily somatropin to SKYTROFA^‡

* Store SKYTROFA in the original package to protect from light. Do not freeze. SKYTROFA can be stored at room temperature (not to exceed 86°F [30°C]) for up to 6 months. Alternatively, SKYTROFA can be stored under refrigeration at 36°F to 46°F (2°C to 8°C) until the expiration date. If refrigerated, keep at room temperature for 15 minutes before use. Do not use SKYTROFA beyond the expiration date or 6 months after the date it was ﬁrst removed from refrigeration (whichever is earlier).

^† In a clinical trial that compared once-weekly SKYTROFA with a daily somatropin in 161 children with pediatric GHD who previously had not been on treatment. The primary endpoint from the clinical trial was annualized height velocity (AHV) at 52 weeks. AHV at 52 weeks was 11.2 cm/year for SKYTROFA versus 10.3 cm/year for a daily somatropin.

^‡ SKYTROFA was studied in a 26-week clinical trial investigating the safety, tolerability, and efficacy of SKYTROFA administered once weekly in children with pediatric GHD. The trial included 3 children who previously had not been on treatment and 143 children previously treated with daily growth hormone therapies for ≤ 130 weeks. Safety and tolerability were the primary endpoints.

How SKYTROFA works:

Long-acting, extended release

The innovative technology of SKYTROFA makes once-weekly dosing possible for you and your child.

SKYTROFA delivers somatropin, which is used in daily growth hormone therapies. After your child’s SKYTROFA injection, somatropin slowly begins to release over time. This means that your child will get the medicine they need to grow from their injection over the course of a week.

Established safety profile

Once-weekly SKYTROFA is FDA approved, with an established safety profile.

In a clinical study, some children taking once-weekly SKYTROFA had mild injection-site reactions
Side effects occurring more frequently than with daily somatropin included viral infection, fever, cough, nausea and vomiting, bleeding, diarrhea, stomach area pain, and joint pain and arthritis